Fuan Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company") announces that its wholly-owned subsidiary, Guang'an Kate Pharmaceutical Co., Ltd. (hereinafter referred to as "Guang'an Kate"), recently received a registration approval notice for Diazoxide raw material issued by the U.S. Food and Drug Administration (FDA). The specific details are as follows:
300194SZSE
🚨 Material Event
Announcement on the FDA Registration Approval of Subsidiary's Raw Material Drug
✨ AI Summary
Fuan Pharmaceutical Group Co., Ltd. announced that its wholly-owned subsidiary, Guang'an Kate Pharmaceutical Co., Ltd., received FDA approval for the registration of Diazoxide raw material. This approval indicates that the FDA has completed the technical review of the Drug Master File (DMF), allowing the subsidiary to meet ANDA application requirements. The approval is expected to facilitate customer development and market expansion, positively impacting the company's international business growth.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.